Scientists develop first drug-like compounds to inhibit elusive cancer-linked enzymes – Phys.org

A team of scientists from the University of Michigan Rogel Cancer Center has developed the first drug-like compounds to inhibit a key family of enzymes whose malfunction is associated with several types of cancer, including an aggressive form of childhood leukemia.
The enzymesknown as the nuclear receptor-binding SET domain (NSD) family of histone methyltransferaseshave long been an attractive drug target, but efforts to attack them have previously proved elusive because the shape of the bindin…

Click here to view the original article.